Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOCK5 | Q9H7D0 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | FADS1 | O60427 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 5/20 | 0.36 |
| ▸ | BPTF | Q12830 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416974 | 1.00 | DOCK5 (0.48) | DOCK5METAP2DRD2DRD3POLB | |
| SCHEMBL1650705 | 1.00 | DOCK5 (0.48) | DOCK5METAP2DRD2DRD3POLB | |
| SCHEMBL12654095 | 0.88 | DDB1 (0.43) | DOCK5METAP2LIPEHRH3 | |
| SCHEMBL12654100 | 0.88 | LIPE (0.36) | DOCK5METAP2LIPEHRH3 | |
| SCHEMBL1650437 | 0.88 | LIPE (0.36) | DOCK5METAP2LIPEHRH3 | |
| SCHEMBL1651068 | 0.88 | LIPE (0.36) | DOCK5METAP2LIPEHRH3 | |
| SCHEMBL1650475 | 0.88 | LIPE (0.36) | DOCK5METAP2LIPEHRH3 | |
| SCHEMBL15484518 | 0.87 | DOCK5 (0.47) | DOCK5METAP2DRD2DRD3LMNA | |
| SCHEMBL1650417 | 0.87 | DOCK5 (0.47) | DOCK5METAP2DRD2DRD3LMNA | |
| SCHEMBL1650721 | 0.87 | DOCK5 (0.47) | DOCK5METAP2DRD2DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| EP-2493304-B1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| EP-2493304-B1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-8633190-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| US-8633190-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| US-8633190-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | DOCK5 2597/4885METAP2 3830/4885DRD2 1512/4885 |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | DOCK5 2597/4885METAP2 3830/4885DRD2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.